NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Corcept Therapeutics Incorporated ("Corcept†or the "Company†) (NASDAQ:CORT) securities during the period of October 31, 2024 through December 30, 2025, inclusive ("the Class Period†). If you suffered a loss on your Corcept investments, you have until April 21, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff app. ...

SAN FRANCISCO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against Corcept Therapeutics Inc. (NASDAQ: CORT) and certain of its top executives. The lawsuit, Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525 (N.D. Cal.), seeks to recover losses for investors who purchased CORT common stock between October 31, 2024, and December 30, 2025 The fir ...

Core Points - The Corcept Therapeutics class action lawsuit seeks to represent investors who purchased common stock between October 31, 2024, and December 30, 2025, alleging violations of the Securities Exchange Act of 1934 [1] - The lawsuit claims that Corcept misrepresented the support for its relacorilant New Drug Application (NDA), suggesting it was close to FDA approval despite known concerns from the FDA regarding clinical evidence [1] - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) for the relacorilant NDA, leading to a more than 50% drop in the company's stock price [1] - The FDA's CRL indicated that the clinical studies submitted were insufficient to demonstrate relacorilant's efficacy, and the FDA had previously warned Corcept about significant review issues [1] Company Overview - Corcept Therapeutics is engaged in the discovery and development of medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders, with relacorilant being a lead candidate for treating hypercortisolism [1] - The company has faced significant scrutiny regarding the adequacy of its clinical development program for relacorilant, which has implications for its future product approvals and market performance [1] Legal Context - The Private Securities Litigation Reform Act of 1995 allows investors who suffered losses during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [1] - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [1]

Core Viewpoint - The Corcept class action lawsuit alleges that Corcept Therapeutics and its executives misrepresented the status of their New Drug Application (NDA) for relacorilant, leading to significant financial losses for investors when the FDA issued a Complete Response Letter (CRL) indicating concerns about the clinical evidence supporting the NDA [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit seeks to represent purchasers of Corcept common stock from October 31, 2024, to December 30, 2025 [1]. - The lawsuit is titled Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated and is filed in the Northern District of California [1]. - The allegations include that Corcept misled investors about the FDA's review process and the adequacy of clinical evidence for relacorilant [3][4]. Group 2: FDA Concerns - The FDA had raised concerns about the clinical evidence supporting the NDA for relacorilant, indicating a material risk of non-approval [3]. - On December 31, 2025, Corcept disclosed that the FDA issued a CRL, stating it could not make a favorable benefit-risk assessment without additional evidence [4]. - A redacted copy of the CRL published on January 30, 2026, detailed the FDA's concerns regarding the sufficiency of the clinical studies submitted [5]. Group 3: Legal Process - Investors who suffered losses during the class period can seek to be appointed as lead plaintiff in the lawsuit [6]. - The lead plaintiff will represent the interests of all class members and can select a law firm for litigation [6]. Group 4: Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history [7].

Core Viewpoint - A class action lawsuit has been filed against Corcept Therapeutics Incorporated and certain senior executives for alleged violations of federal securities laws [1] Group 1 - The lawsuit was filed by Bernstein Litowitz Berger & Grossmann LLP in the U.S. District Court for the Northern District of California [1] - The action represents all investors who purchased or otherwise acquired shares of Corcept Therapeutics [1]

Core Viewpoint - A class action lawsuit has been filed on behalf of investors who purchased Corcept Therapeutics common stock between October 31, 2024, and December 30, 2025, indicating potential legal challenges for the company [1]. Company Overview - Corcept Therapeutics is a pharmaceutical company focused on developing medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol [1].

Core Insights - The article discusses the background and achievements of Brendan, highlighting his academic and professional journey in the pharmaceutical and biotechnology sectors. Group 1: Academic Background - Brendan completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] Group 2: Professional Experience - He worked for Merck, a major pharmaceutical company, from 2009 to 2013 [1] - Brendan has experience in biotech, including startups such as Theravance and Aspira, before joining Caltech [1] - He was the first employee and co-founder of 1200 Pharma, which spun out of Caltech and secured significant investment in the eight figures [1] Group 3: Investment Focus - Brendan remains an avid investor, concentrating on market trends, particularly in biotechnology stocks [1]

Core Viewpoint - Hi-View Resources Inc. has announced an increase in its non-brokered private placement offering to 6,750,000 units at a price of $0.30 per unit, aiming for gross proceeds of up to $2,025,000 [1] Group 1: Private Placement Details - The offering consists of one common share and half of one transferable common share purchase warrant per unit, with each whole warrant allowing the purchase of an additional share at $0.45 for 24 months [1] - Proceeds from the placement will be used for general corporate purposes, including arm's-length payables [2] - Finders' fees of up to 10% may apply to the private placements, and all securities issued will be subject to a hold period of four months and one day [2] Group 2: Company Overview - Hi-View Resources Inc. is a publicly listed mineral exploration company focused on gold, silver, and copper assets in the Toodoggone region of northern British Columbia [4] - The company holds over 27,791 hectares across various projects, including the Lawyers East Project, Borealis Project, and Golden Stranger Project, all of which are high-priority targets [4] - Additional assets include the Nub and Saunders properties, with ongoing option agreements for Northern Claims and Harmon Peak, and an additional 1,300 hectares under mineral claim application [4]

Corcept Therapeutics shares are approaching critical lows. What’s pressuring CORT?Appeals Court Upholds Ruling Against CorceptCorcept had argued that Teva's label for its generic version of Korlym, a drug used to treat Cushing's syndrome, would induce doctors to follow patented dosing methods involving mifepristone and strong CYP3A inhibitors such as ketoconazole. The appeals court agreed with the lower court that there was no proof doctors had used, or were likely to use, those specific regimens, especiall ...

Corcept Therapeutics (NASDAQ:CORT) is one of the 17 biotechnology stocks with more than 50% upside. On February 2, Edward Nash from Canaccord Genuity reaffirmed his Buy rating for Corcept Therapeutics (NASDAQ:CORT). He forecasted a price target of $100, which leads to almost 161% upside potential on the stock. Nestor Rizhniak/Shutterstock.com Nash noted that the CRL issued by the U.S. FDA for the relacorilant NDA confirms their prior expectations. Their model already accounted for the need to conduct a ...